Stock-Based Compensation

3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

The table below summarizes the impact of recording stock-based compensation expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss during the three months ended March 31, 2019 and 2018:



	Three Months Ended March 31,
	2019		2018
Cost of goods sold	$	227	$	236
Operating expenses:
Research and development	332		333
Clinical and regulatory affairs	186		176
Marketing and sales	709		1,114
General and administrative	907		1,162
Total operating expenses	2,134		2,785
Total	$	2,361	$	3,021